Categories
Health

Pharmacies Are Getting into the Psychological Well being Market

CVS, which merged with insurer Aetna three years ago, plans to use its mental health pilot program to reduce overall health costs, said Dr. Servant. Mental health problems that are not addressed turn into crises, he added. “Our goal is therefore to make mental health services accessible and locally available so that we can address these issues before they get worse and lead to significant morbidity and poor outcomes.”

Vaile Wright, senior director of health care innovation for the American Psychological Association, says removing barriers to psychiatric care by making providers more accessible is helpful. “Cost is.”

Psychiatrists take out less insurance than other types of doctors, and many psychologists, social workers, and others who offer therapies also decline insurance because they say that insurance payments are relatively low and managed care companies sometimes do intrusive audits undergo.

The mental health services provided by CVS MinuteClinics are covered by many major health insurers and Employee Assistance Program programs, a spokeswoman said.

“The pricing options without insurance range from $ 129 for an initial assessment to $ 69 for a 30-minute session, with lots of options in between,” she added.

At Walmart, the first therapy session is $ 60, and the 45-minute follow-up visits are $ 45, according to the company’s website.

If you’re considering using a retail location to get therapy, be sure to ask the same questions you would ask any new therapist, experts advise. Some examples are:

  • Where did you get trained?

  • What kind of license do you have?

  • What is your specialty?

  • How will we monitor my progress?

  • How long does my session last and how many sessions do I have?

  • Is there a follow up if I need a transfer?

  • How much is it?

  • How is my data stored and shared?

If you identify yourself as LGBT or are a member of another minority group, or if you already know that you have a specific illness such as anxiety or depression, it is helpful to know if the therapist has worked with similar populations in the past and Alfiee Breland-Noble , Researcher on health inequalities and founder of the AAKOMA project, a non-profit mental health organization for adolescents and their families.

Categories
Health

Pfizer and BioNTech start the method of searching for full U.S. approval for his or her Covid vaccine

Vials containing the Pfizer-BioNTech Covid-19 vaccine on Thursday, February 11, 2021 at the vaccination site of the Sun City Anthem Community Center in Henderson, Nevada, USA.

Roger Kisby | Bloomberg | Getty Images

Pfizer and German drug maker BioNTech announced that they have begun filing for full approval of their Covid-19 vaccine for people aged 16 and over in the United States. This makes the companies the first in the nation to apply for full regulatory approval.

The Food and Drug Administration issued emergency approval for their Covid vaccine at the end of December. Since then, Pfizer has distributed 170 million doses in the US, with the goal of having 300 million doses by the end of July.

“We are proud of the tremendous progress we have made in working with the US government to deliver vaccines to millions of Americans since December,” said Albert Bourla, Pfizer CEO, in a statement. “We look forward to working with the FDA to complete this ongoing filing and support its review with the aim of ensuring full regulatory approval for the vaccine in the months ahead.”

Pfizer needs to demonstrate that it can reliably manufacture the vaccines in order to get full clearance. If approved, companies could market their shots directly to consumers and potentially change the pricing of the cans. It also allows the shot to stay in the market once the pandemic is over and the US is no longer considered an “emergency”.

It usually takes the FDA about a year or more to determine whether a drug is safe and effective for the general public. Due to the once in a century pandemic that killed nearly 600,000 people in the United States, the FDA allowed the gunshots to be used as part of an emergency clearance.

The permit grants conditional approval based on data for two months. It’s not the same as a biological license application that requires six months of data and ensures full approval. Companies apply for approval on a “rolling filing” basis, which speeds the review process by allowing the FDA to review new data as soon as the company receives it.

“The BLA filing is an important cornerstone in achieving long-term herd immunity and future COVID-19 containment,” said Dr. Ugur Sahin, CEO and Co-Founder of BioNTech, in a statement. “We are excited to be working with US regulators to apply for approval of our COVID-19 vaccine based on our key Phase 3 study and follow-up data.”

Early data from 12,000 vaccinated people aged 16 and over in this Phase 3 study showed that the shots were 91.3% effective at getting the disease up for up to six months after the second dose and 95.3% effective against severe Covid as defined by the FDA. The companies said on April 1st. The data also showed “a favorable safety and tolerability profile,” they said at the time.

The companies are awaiting FDA emergency approval to use their vaccine in children ages 12-15 and intend to apply for a full license once they have six months of data.

They said in late March that the vaccine was 100% effective in a clinical study involving more than 2,000 adolescents. They also said the vaccine produced a “robust” antibody response in the children that outperformed that in a previous study in older teenagers and young adults. The side effects were generally consistent with those seen in adults, they added.

This is the latest news. Please try again.

Categories
Health

How Meals Impacts Psychological Well being

The results were remarkable for several reasons. The diet benefited mental health even though the participants did not lose any weight. People also saved money by eating more nutritious foods, which shows that eating healthy can be economical. Prior to the study, participants spent an average of $ 138 per week on groceries. Those who switched to healthy eating cut their food bills to $ 112 per week.

The foods we recommend were relatively cheap and available in most grocery stores. These included canned beans and lentils, canned salmon, tuna and sardines, and frozen and conventional products, said Felice Jacka, the study’s lead author.

“Mental health is complex,” said Dr. Jacka, Director of the Food & Mood Center at Deakin University in Australia and President of the International Society for Nutritional Psychiatry Research. “Eating a salad won’t cure depression. But a lot can be done to lift your spirits and improve your sanity, and it can be as simple as increasing your intake of plants and healthy foods. “

A number of randomized trials have reported similar results. In a study of 150 adults with depression published last year, researchers found that people who followed a fish oil-fortified Mediterranean diet for three months had greater reductions in symptoms of depression, stress and depression after three months compared to a control group Had anxiety.

However, not every study has produced positive results. For example, a large, year-long study published in JAMA in 2019 found that a Mediterranean diet reduced anxiety, but didn’t prevent depression in a group of high-risk people. Taking supplements such as vitamin D, selenium, and omega-3 fatty acids had no effects on depression or anxiety.

Most mental health professionals have not followed dietary recommendations, partly because experts say more research is needed before they can prescribe a particular mental health diet. However, public health experts in countries around the world have begun encouraging people to adopt behaviors such as exercise, sound sleep, a heart-healthy diet, and avoiding smoking that can reduce inflammation and have benefits for the brain. The Royal Australian and New Zealand College of Psychiatrists issued guidelines for clinical practice urging doctors to consider diet, exercise, and smoking before starting any medication or psychotherapy.

Individual clinicians also include nutrition in their work with patients. Dr. Drew Ramsey, a psychiatrist and clinical assistant professor at Columbia University College for Physicians and Surgeons in New York, begins his sessions with new patients by taking their psychiatric history and then examining their diet. He asks what they eat, learns about their favorite foods, and finds out if foods he thinks are important for the gut-brain connection are missing in their diet, such as plants, seafood, and fermented foods.

Categories
Health

CDC can contemplate lifting indoor Covid masks mandates now

Dr. Scott Gottlieb said the Centers for Disease Control and Prevention may begin considering lifting mandates on inner masks as more Americans become vaccinated.

“I think we should start lifting these restrictions as aggressively as we put them in place,” said Gottlieb. “We need to maintain the credibility of health officials to potentially re-implement some of these regulations next winter when we see outbreaks again.”

The former FDA chief in the Trump administration added that “the only way to gain public credibility is to show that you are ready to relax these regulations if the situation improves.”

The US Covid positivity rate is 3.6%, an all-time low according to Johns Hopkins University. It’s a big difference from April 2020 when the positivity rate hit nearly 23%, meaning almost a quarter of all tests done were positive.

In an interview on CNBC’s “The News with Shepard Smith” Thursday night, Gottlieb stated that the general outlook for vaccination in the US “looks very good,” especially as the FDA prepares to sell Pfizer’s Covid vaccine for 12-15 Years to admit – age soon.

“Even if vaccination rates slow down, we will continue to try to vaccinate more people … but I think these profits are limited and the summer is looking very good,” said Gottlieb.

Disclosure: Scott Gottlieb is a CNBC employee and a member of the boards of directors of Pfizer, the genetic testing startup Tempus, and the biotech company Illumina. Pfizer has signed a manufacturing agreement with Gilead for Remdesivir. Gottlieb is also co-chair of Norwegian Cruise Line Holdings and Royal Caribbean’s Healthy Sail Panel.

Categories
Health

Need a Coronavirus Vaccine? U.S. Pharmacies Say Stroll Proper In

Just a few weeks ago, people were sneaking across state lines, designing websites to search the internet, and even trying to pay for coronavirus vaccination appointments.

In much of the US, getting vaccinated can be as simple as entering a pharmacy.

Earlier this week, President Biden urged pharmacies to provide walk-in vaccinations to encourage reluctant people to get the shot. He also announced a new federal website and phone number that will help people find the website that is closest to them.

“We’re going to make it easier than ever to get vaccinated,” Biden said on Tuesday.

Chains like Walmart, Walgreens, Safeway, and Stop & Shop have announced that they are now offering vaccinations for walk-in customers in some locations or in mobile clinics. Other pharmacies preceded the president’s announcement. Rite Aid said there would be a limited number of walk-ins last week, for example. Biden’s administration is expanding access to meet its goal of getting at least the first shot at 70 percent of American adults by July 4th.

Many of the chains qualified the offer and found that walk-ins are subject to availability and that it is better to make an appointment on the same day as well.

Federal health officials have also ordered drug stores and grocery pharmacies to offer second doses of the vaccine to people who received their first shot from another provider.

The Biden government is hoping for a surge in vaccinations before the Food and Drug Administration expects the Pfizer BioNTech vaccine to be approved for adolescents ages 12-15 early next week. The president has said age group is important in the fight against the virus because, while adolescents are not as susceptible to serious illnesses, they can still get sick and infect others.

Convenience isn’t the only way officials have encouraged people to get vaccinated. In exchange for a free vaccination against a potentially fatal disease, you can now get a ticket to a baseball game, a stiff drink, or $ 100.

Categories
Health

‘This virus will not be going away’

Stephane Bancel, CEO of Moderna, attends the Forbes Healthcare Summit 2019 at Jazz at Lincoln Center on December 5, 2019 in New York City.

Steven Ferdman | Getty Images

Stephane Bancel, CEO of Moderna, said Thursday the company expects more Covid-19 variants to hit the market in the coming months as the southern hemisphere enters the fall and winter seasons.

Talking to investors about a first-quarter earnings call, Bancel said people will likely need booster shots of his two-dose Covid-19 vaccine as the virus circulates around the world.

“There are always new worrying variants around the world. And we believe that in the next six months, when the southern hemisphere enters autumn and winter, more worrying variants may emerge,” Bancel said. The southern hemisphere includes Africa, Australia, most of South America, and parts of Asia. “We believe booster vaccinations will be needed as we believe the virus will not go away.”

The CEO’s comments come a day after the company announced that a booster shot of its vaccine triggered a promising immune response against variants B.1.351 and P.1, which were first identified in South Africa and Brazil, respectively. The variants have since expanded to other countries, including the United States

The data are preliminary and have not yet been reviewed by colleagues.

Moderna’s vaccine requires two doses four weeks apart. As with Pfizer and Johnson & Johnson, the shot against Covid is very effective, although company executives and officials now say they expect this strong protection to wear off over time. Pfizer’s vaccine is also a two-dose therapy, while the J&J immunization is just one burst.

Earlier Thursday, Moderna said the sale of its successful vaccine helped generate its first-ever quarterly profit.

Moderna’s Covid-19 vaccine had sales of $ 1.7 billion, according to earnings reports. The company also raised its 2021 sales forecast for its vaccine to $ 19.2 billion from its previous forecast of $ 18.4 billion. Bancel said the company is “actively involved” in discussions and agreements for 2022 with all governments it currently serves.

Earlier this week, rival Pfizer also raised its vaccine sales forecast, forecasting total annual sales of $ 26 billion.

Categories
Health

The pandemic has made some People rethink the each day bathe.

Robin Harper, an administrative assistant at a Martha’s Vineyard preschool, grew up taking a shower every day. “It’s what you did,” she said.

But when the pandemic forced her inside and away from the public, she started showering once a week. The new practice felt environmentally virtuous, practical, and liberating – and it’s stayed.

“Don’t get me wrong – I like showering,” said Ms. Harper, 43, who has returned to work. “But it’s an off my plate thing. I’m a mom, I work full time and it’s one less thing to do. “

The pandemic has turned the use of zippered pants on its head and changed the eating and drinking habits of many people. And there is now evidence that some Americans have become more Spartan about ablutions.

Parents say their teenage children don’t take daily showers. After the UK news media reported a YouGov poll showing that 17 percent of people in the UK had given up daily showers during the pandemic, many on Twitter said they did the same.

Heather Whaley, 49, a writer in Redding, Connecticut, said her shower use fell 20 percent over the past year. After the pandemic forced her to lock down, she began to wonder why she showered every day.

“Do I? I want you to say.” Taking a shower was less a question of function than a question of doing something for myself that I enjoyed. “

(In a previous version of this article, the city name was misspelled.)

Categories
Health

Medicare must OK rule giving seniors entry to FDA-approved medical units

Mina De La O | Digital vision | Getty Images

Dr. Anand Shah is an oncologist and former FDA Assistant Commissioner and former Chief Medical Officer of the Center for Medicare & Medicaid Innovation. He is also an advisor to Morgan Stanley.

Navigating public and commercial health insurance to cover innovative medical products can be a never-ending cycle of bureaucracy.

Medical technologies classified as “safe and effective” by the Food and Drug Administration – the global gold standard for regulating drugs and devices – are not always covered by the Centers for Medicare & Medicaid Services, adding the added hurdle for companies Proof of their requirements must be met Product is “reasonable and necessary”.

Unlike medications, which are typically covered by CMS immediately after FDA approval, seniors can only access many FDA cleared or approved medical diagnoses and devices if they can participate in a CMS approved clinical trial. These studies can take years – additional data and a lengthy regulatory process to determine coverage criteria – and in the meantime sustain potentially life-saving medical interventions from Medicare beneficiaries.

A new policy, due to go into effect in mid-March, would have allowed seniors and their doctors to decide whether or not they needed these devices. However, it was postponed along with other pending regulations when the Biden Administration took office. The proposed Medicare Innovative Technologies Coverage Policy, postponed until May 15 for regulatory review, leverages existing FDA legal expertise under the Breakthrough Devices program to identify a limited number of promising medical technologies, and offers these products a short Medicare warranty. granted on the day of FDA approval.

The proposed policy would be a critical step forward for Medicare beneficiaries to make informed decisions about their care.

Currently, the FDA has approved, authorized, or cleared at least 26 breakthrough diagnoses and devices. These medical products include in vitro diagnostic and imaging platforms for implants and wearable devices that cover a range of diseases, including Ebola, traumatic brain injury, severe emphysema, and heart disease.

As an oncologist who helped develop this medical device policy at CMS, I have looked after many patients who have not had access to state-of-the-art tests such as next-generation DNA sequencing as part of a cancer screening because Medicare does not allow them. The same product can often be obtained by the patient through a commercial insurance policy, which many do not get under the Medicare program after aging. As a last resort, the patient has no choice but to pay out of pocket.

Seniors deserve access to FDA-named breakthrough medical devices – narrowly defined by Congress to include the most promising new technologies, such as those that can treat life-threatening or irreversibly debilitating conditions – once the FDA deems them safe and effective.

It is important that the proposed rule maintain the same high standards required by both the FDA and the CMS. In addition, the existing FDA requirements for post-market surveillance will be maintained. This policy bridges the void for patients who would otherwise not have access to the latest FDA authorized technology while waiting for CMS coverage. Still, it encourages researchers to continue collecting real-world evidence of health outcomes that are specific to Medicare beneficiaries.

Patient protection is maintained as MCIT uses existing procedures to restrict access to new technology when safety or efficacy concerns arise.

There is no disadvantage in approving this policy change. Seniors will have more treatment options, and medical technology innovators can work with CMS to carefully examine these patients over a four-year period, generating meaningful real-world evidence to prove that a new device is “sensible and necessary.” “Is Medicare coverage decision and potentially offers more permanent security.

This policy also encourages early investors to support innovation for the most pressing medical conditions as it creates a clear and predictable path – from investing to developing medical products to regulatory review and subsequent patient access.

If the federal government wants to incentivize investment in developing transformative medical innovations and expand choices for our seniors while promoting rigorous evidence generation, MCIT offers a clear way forward. Too many lives depend on it.

Correction: This editorial has been updated to correct the name of the agency that needs to approve the rule in the headline. It’s CMS.

Categories
Health

Dad and mom Are Reluctant to Get Their Kids Vaccinated for Covid-19, Ballot Exhibits

The willingness of the American public to get a Covid vaccine is reaching a saturation point, according to a new national poll. This is yet another indication that achieving widespread immunity in the United States is becoming increasingly difficult.

Only 9 percent of respondents said they hadn’t received the shot yet, but they intended to, according to the poll published in the April issue of the Kaiser Family Foundation’s Vaccine Monitor. And with federal approval of the Pfizer vaccine for teens 12-15 years old imminent, parents’ willingness to get their children vaccinated is also limited, the survey found.

Overall, just over half of respondents said they had received at least one dose of the vaccine, which is in line with data from the Centers for Disease Control and Prevention.

“We are in a new phase of vaccine demand,” said Mollyann Brodie, executive vice president of Kaiser’s Public Opinion and Survey Research Program. “There won’t be a single strategy to drive demand from all of the remaining people. There will have to be a lot of individually targeted efforts. The people who are still on the fence have logistical barriers, information needs and many do not yet know whether they are authorized. Any strategy could get a small number of people to get vaccinated, but all in all, it could be very important. “

As more scientists and public health experts conclude that the country is unlikely to reach the herd immunity threshold, the Biden government has stepped up efforts to reach those who still hesitate. On Tuesday, the government announced steps to encourage more pop-up and mobile vaccination clinics, and to distribute the recordings to general practitioners and pediatricians, as well as local pharmacies.

The survey also found that confidence in the Johnson & Johnson vaccine had taken a significant blow after the 10-day hiatus, while authorities investigated rare cases of life-threatening blood clots in people who took it. While 69 percent of respondents said they had confidence in the safety of the vaccines manufactured by Pfizer and Moderna, only 46 percent believed the vaccine from Johnson & Johnson was safe. Among adults who were not vaccinated, one in five said the news of the Johnson & Johnson shot had caused them to change their minds about a Covid-19 vaccine.

The poll found that some of the most prominent Republicans were making some progress. In this group, 55 percent said they had or intended to get a shot, up from 46 percent in March. The percentage who will “definitely not” receive the vaccine also drops from 29 percent in March to 20 percent.

The results were based on telephone surveys of a nationally representative sample of 2,097 adults from April 15 to 29.

The so-called “wait and see” group – people looking for more information before making a decision – was within 15 percent, constant from 17 percent in March. The proportion of people who said they were only vaccinated when required by employers or schools was 6 percent, compared with 7 percent in March.

The Pfizer vaccine is expected to be approved within a few days for children ages 12-15. Among parents surveyed, three in ten said they would vaccinate their children immediately, and 26 percent said they wanted to see how the vaccine works. These numbers largely reflected the zeal with which these parents themselves sought vaccination.

Updated

May 6, 2021, 9:42 a.m. ET

Similarly, 18 percent said they would only do this if a child’s school required it, and 23 percent said they would definitely not have their children vaccinated.

A consortium of universities that includes Harvard, Northeastern and Rutgers conducted online surveys during the pandemic and recently focused on parents. The group’s most recent poll, conducted in April and reaching 21,733 adults in 50 states, found that the gap between mothers and fathers when it comes to the vaccine for children had widened.

The resistance of fathers seems to be weakening somewhat and has fallen from 14 percent since February to 11 percent. But more than a quarter of mothers, the researchers say, still say they are “extremely unlikely” to vaccinate their children. Both sexes are more resistant to the vaccine in younger children than in teenagers. Other research shows that mothers tend to have more influence on the final decision than fathers.

Parents’ answers could change over time, experts say. Just as adults were far less hesitant last summer, when the vaccine was still a concept, parents who were interviewed a few weeks ago when the upcoming approval for children under 16 had not been fully discussed could possibly be more likely to point to a hypothetical situation than responding to a reality.

However, pediatricians and others who are believed to be trusted sources of information are already aware that there is still much work to be done to increase the confidence of vaccines in this newest cohort.

Dr. Sean O’Leary, a Denver pediatrician who is vice chairman of the American Academy of Pediatrics’ infectious diseases committee, predicted that just as adults had flooded Covid vaccine providers in the first few weeks of distribution, parents and pent-up teenagers would too pounce on it at the beginning.

Dr. However, O’Leary, who often speaks to pediatricians about how to motivate patients to accept vaccinations, fears the slowdown will inevitably occur. To convince reluctant parents, he said, “We need to have the vaccine available in as many places as possible.”

He added, “When parents and patients are in the pediatrician’s office and the doctor can say, ‘Hey, I have it,’ it can kick start saying, ‘Let’s go ahead and do this.” ”

Categories
Health

EU prepared to speak wave of IP rights after US backs transfer

Ursula von der Leyen, European Commission president.

Bloomberg | Bloomberg | Getty Images

LONDON – The European Union has said it is ready to discuss surrendering intellectual property rights for Covid-19 vaccines after the US announced it would support the initiative.

The proposed patent waiver, which aims to boost global production of Covid-19 vaccines, has proven controversial for European lawmakers, with some supporting the move while others strongly oppose it. Proponents of the idea say it is crucial to increase vaccination rates in low-income countries. So far, the European Commission, the EU executive, has expressed doubts about the renunciation of intellectual property rights.

On Thursday, the President of the European Commission, Ursula von der Leyen, said her team was open to “discuss any proposals that would address the crisis in an effective and pragmatic way”.

“Therefore, we are ready to discuss how the US proposal to remove intellectual property protection for Covid-19 vaccines could help achieve this goal,” she said during a speech.

It comes after the White House announced on Wednesday that it was in favor of the abolition of intellectual property rights, citing the “exceptional circumstances of the Covid-19 pandemic”.

The move caused stocks of large pharmaceutical companies that developed Covid-19 shots to decline.

However, the announcement received praise from the World Health Organization. WHO Director General Tedros Adhanom Ghebreyesus said the US decision was a “monumental moment in the fight against Covid-19”.

The GAVI Vaccine Alliance also welcomed President Joe Biden’s stance, recognizing “the importance of the government’s commitment to increasing raw material production.”

Milestone proposal

The landmark proposal to renounce intellectual property rights was jointly presented to the World Trade Organization by India and South Africa in October. However, a handful of countries have blocked the proposal. This includes the UK, Switzerland, Japan, Norway, Canada, Australia, Brazil, the EU and – so far – the US.

“In the short term, however, we are calling on all vaccine-producing countries to allow exports and to avoid measures that disrupt the supply chain,” said von der Leyen on Thursday.

The EU has hailed itself as a top exporter of Covid-19 vaccines and has criticized countries like the UK for failing to take similar measures.

A medical worker prepares a syringe of AstraZeneca vaccine in a local sports hall that has been converted into a vaccination center in Ventspils, Latvia.

GINTS IVUSKANS | AFP | Getty Images

“While others keep their vaccine production to themselves, Europe is the world’s largest exporter of vaccines. To date, more than 200 million vaccine doses made in Europe have been shipped to the rest of the world,” said von der Leyen.

The EU, a group of 27 nations, got off to a slow start with vaccine adoption. Vaccinations have steadily increased, however, and the block expects 70% of adults to be vaccinated by July.

“The US has a similar goal. This shows how well our vaccination campaigns have aligned,” added von der Leyen.

The latest data shows Israel, the UK, the US and Chile lead the way in the number of Covid-19 shots given to date. However, the figures also show that vaccination rates in the EU are well above the world average, which was not the case a few weeks ago.